Immunophotonics
Immunophotonics, Inc. is a privately held biotech developing a first-in-class drug (IP-001) to reduce metastasis formation and prevent cancer recurrence in patients with solid tumors. IP-001 induces tumor-specific antitumor immune activation with sustained anticancer immune function. Safety and signs of efficacy have been demonstrated in >100 patients treated and the pivotal market access trial planned to initiate in early 2026.
Date, time and room information
May 6, 15:45 - 16:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Tumor-Specific Immune Activation to Prevent Cancer Recurrence
Speaker information
| Name | Position | Institution |
|---|---|---|
| Theresa Visarius | Vice President Business Development & Managing Director of Immunophotonics Switzerland | Immunophotonics |
Further information for the sponsor website
